Thrivent Financial for Lutherans
SWTX

Thrivent Financial for Lutherans’s SpringWorks Therapeutics SWTX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,745
Closed -$334K – 2496
2023
Q2 		$334K Sell
12,745
-12,917
-50% -$339K ﹤0.01% 2307
2023
Q1 		$661K Sell
25,662
-38,871
-60% -$1.14M ﹤0.01% 2009
2022
Q4 		$1.68M Buy
+64,533
New +$1.59M ﹤0.01% 1370

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thrivent Financial for Lutherans's SWTX Position: Q3 2023 in Review

Thrivent Financial for Lutherans sold out of SpringWorks Therapeutics (SWTX) in Q3 2023, closing a stake of 12,745 shares — an estimated $334K sold.

Thrivent Financial for Lutherans first reported a position in SWTX in Q4 2022 and held it in 3 quarters. The position peaked at $1.68M in Q4 2022. 147 funds tracked by Wall St. Rank hold SWTX as of Q3 2023.

  • Thrivent Financial for Lutherans reported no remaining SpringWorks Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 12,745 SpringWorks Therapeutics shares in Q3 2023, an estimated $334K.
  • Thrivent Financial for Lutherans first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 3 quarters.
  • Thrivent Financial for Lutherans's SpringWorks Therapeutics position peaked at $1.68M in Q4 2022.
  • 147 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2023, filed 14 Nov 2023.